Arvinas Inc (ARVN) Stock Price, Quote & News

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders f...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 535 1456

Website: www.arvinas.com

Address:

5 Science Park, 395 Winchester Avenue, New Haven, United States

Thestocktraderhubzee Oct. 23 at 10:03 AM

WATCHLIST OCT 23 2025. $BURU Nuburu shares are trading higher after the company entered into a strategic framework agreement with Nuburu Defense and Maddox Defense to establish a joint venture company. $ARVN Arvinas To Present Preclinical Data For ARV-806 At 2025 At AACR-NCI-EORTC International Conference In Boston $HON Honeywell International Expects To Complete Separation Of Solstice Advanced Materials Business On Oct. 30, Aerospace Technologies Operations In H2 2026 $SLMT Solmate Infrastructure Provides Update On Its Validator Operations, Data Center Selection, M&A Strategy, And $300M Oversubscribed Pipe Financing And Plans To File The Registration Statement For Pipe Investor Shares By November 22, 2025 $GPUS Hyperscale Data Announces Intent To Launch On-Demand NVIDIA Graphics Processing Unit Cloud Platform From Michigan AI Data Center Campus

0 · Reply

TwongStocks Oct. 22 at 8:04 PM

$ARVN Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics https://ir.arvinas.com/news-releases/news-release-details/arvinas-present-preclinical-data-arv-806-protac-kras-g12d

0 · Reply

OpenOutcrier Oct. 20 at 12:15 PM

$ARVN (-1.5% pre) Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy https://ooc.bz/l/81134

1 · Reply

buyandsold Oct. 17 at 11:21 PM

$ARVN NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that new data for vepdegestrant will be presented at the European Society for Medical Oncology (ESMO) Congress to be held October 17 through 21, 2025, in Berlin, Germany.

0 · Reply

buyandsold Oct. 17 at 11:18 PM

$ARVN monday's vepdeg presentation can hardly be expected to be of any consequence give that PFE knows the data and kicked it to the kerb

1 · Reply

JBSchulte Oct. 16 at 5:54 PM

$ARVN so Goldman downgrades the stock to 6 and it pops above 10? Any theories as to why?

1 · Reply

SaluteYourShorts Oct. 16 at 5:24 PM

$ARVN trimming a little

0 · Reply

TwongStocks Oct. 15 at 9:30 PM

$ARVN Logos Global Management filed a new 13D this afternoon. https://www.sec.gov/Archives/edgar/data/1792126/000093583625000639/xslSCHEDULE_13D_X01/primary_doc.xml Reporting beneficial ownership of 2.5m shares, 3.4%. Under Item 5(e), they report that they ceased to be beneficial owners of 5% on Oct 13. As a result, they will no longer be required to make 13D filings until they go back over 5%. Exhibit 99.2 lists their sales over the past 60 days. https://www.sec.gov/Archives/edgar/data/1655759/000093583625000639/ex992.htm

0 · Reply

JarvisFlow Oct. 15 at 11:25 AM

Goldman Sachs has adjusted their stance on Arvinas ( $ARVN ), setting the rating to Sell with a target price of 8 → 6.

3 · Reply

SaluteYourShorts Oct. 13 at 7:28 PM

$ARVN nice little 225k print there

0 · Reply

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 22, 2025, 4:00 PM EDT - 3 days ago

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 20, 2025, 4:15 AM EDT - 5 days ago

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

PFE

Oct 13, 2025, 7:00 AM EDT - 12 days ago

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 5, 2025, 2:00 PM EDT - 20 days ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 1, 2025, 7:00 AM EDT - 24 days ago

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Sep 17, 2025, 5:50 PM EDT - 5 weeks ago

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

PFE

Sep 17, 2025, 4:30 PM EDT - 5 weeks ago

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Sep 9, 2025, 10:12 AM EDT - 6 weeks ago

Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 29, 2025, 7:00 AM EDT - 2 months ago

Arvinas to Participate in Upcoming Investor Conferences

Aug 8, 2025, 4:05 PM EDT - 2 months ago

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Aug 6, 2025, 1:24 PM EDT - 2 months ago

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 2 months ago

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 4:05 PM EDT - 3 months ago

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 9, 2025, 7:00 AM EDT - 3 months ago

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Jun 13, 2025, 7:00 AM EDT - 4 months ago

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Jun 6, 2025, 7:00 AM EDT - 5 months ago

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Jun 5, 2025, 8:28 AM EDT - 5 months ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

May 31, 2025, 8:06 AM EDT - 5 months ago

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

PFE

May 31, 2025, 8:00 AM EDT - 5 months ago

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 30, 2025, 7:00 AM EDT - 5 months ago

Arvinas to Present at Jefferies Global Healthcare Conference

May 16, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

May 15, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

May 14, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

May 13, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

May 12, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

May 11, 2025, 10:00 AM EDT - 5 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 9, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

May 8, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

May 7, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation

May 6, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out

May 5, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out

May 4, 2025, 4:17 PM EDT - 6 months ago

Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case

Thestocktraderhubzee Oct. 23 at 10:03 AM

0 · Reply

TwongStocks Oct. 22 at 8:04 PM

0 · Reply

OpenOutcrier Oct. 20 at 12:15 PM

1 · Reply

buyandsold Oct. 17 at 11:21 PM

0 · Reply

buyandsold Oct. 17 at 11:18 PM

$ARVN monday's vepdeg presentation can hardly be expected to be of any consequence give that PFE knows the data and kicked it to the kerb

1 · Reply

JBSchulte Oct. 16 at 5:54 PM

$ARVN so Goldman downgrades the stock to 6 and it pops above 10? Any theories as to why?

1 · Reply

SaluteYourShorts Oct. 16 at 5:24 PM

$ARVN trimming a little

0 · Reply

TwongStocks Oct. 15 at 9:30 PM

0 · Reply

JarvisFlow Oct. 15 at 11:25 AM

Goldman Sachs has adjusted their stance on Arvinas ( $ARVN ), setting the rating to Sell with a target price of 8 → 6.

3 · Reply

SaluteYourShorts Oct. 13 at 7:28 PM

$ARVN nice little 225k print there

0 · Reply

SaluteYourShorts Oct. 13 at 7:21 PM

$ARVN and best of all.. it's quiet here.

2 · Reply

SaluteYourShorts Oct. 13 at 7:19 PM

$ARVN 94% institutional holding

0 · Reply

SaluteYourShorts Oct. 13 at 7:18 PM

$ARVN 100m buy back ... 4 or 5 years of cash .. could cont up strong

0 · Reply

SaluteYourShorts Oct. 13 at 7:16 PM

$ARVN lighting up ... unusal opts

0 · Reply

biopuzzle Oct. 13 at 7:12 PM

$ARVN My guess is the Big Boys are returning...

1 · Reply

biopuzzle Oct. 13 at 3:26 PM

$ARVN a pennant is forming. I like it.

0 · Reply

outlawinvestor1 Oct. 13 at 2:30 PM

$CCCC i've started a position here today and will add along the way. only a matter of time before the market realizes the opportunity here. my favorite tpd companies right now are $CCCC $GLUE $ARVN and $NRIX .

1 · Reply

georgenobest Oct. 11 at 6:42 PM

$ARVN CATX more than 300% upside. Catalyst coming next week. The move just started https://in.investing.com/news/analyst-ratings/btig-initiates-coverage-on-perspective-therapeutics-stock-with-buy-rating-93CH-5038968

0 · Reply

Social_Idiot Oct. 8 at 5:43 PM

$ARVN Best decision that I've made all year.

1 · Reply

buyandsold Oct. 7 at 12:57 AM

$ARVN well that was degrading Time to liquidate when nobody believes your encourgaing P1 data

1 · Reply

jjrrjjrr Oct. 6 at 6:11 PM

$ARVN $PSNL $PACB $XRAY NFA

1 · Reply

outlawinvestor1 Oct. 6 at 3:23 PM

$ARVN @MOTP perhaps resistance at $11/12 due to drop to ~$6 after vepdeg ph3 readout combined with continued investor caution. despite my own negative feelings about management, i believe it's a buy at current levels and this is a gift. despite vepdeg upset, it's still an active drug that will be used after approval. on top of that, they have 3 shots on goal in the clinic now (arvn102 (lrrk2), arvn393 (bcl6), and arvn?? (krasg12d) + an oral protac platform that has been validated in onc with vepdeg (and now partially in neuro). this stock is still trading below cash, thus the market is ascribing negative value to a company that has all of the above. if they were to be acquired today, i would imagine that they could command any where from $4-8 billion without doing the math.

1 · Reply

Market Cap	672.51M
Revenue (ttm)	263.40M
Net Income (ttm)	-198.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-75.51%
Debt to Equity Ratio	0.00

Volume	3,459,500
Avg Vol	2,100,256
Day's Range	N/A - N/A
Shares Out	73.42M
Stochastic %K	28%
Beta	2.39
Analysts	Sell
Price Target	$12.12